These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 10470179)

  • 1. Trofosfamide in patients with pancreatic cancer.
    Schmidt-Sandte W; Dageförde J; Klapdor R; Wagner T; Wiedemann GJ
    Anticancer Res; 1999; 19(4A):2485-7. PubMed ID: 10470179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of trofosfamide in patients with advanced pretreated soft tissue sarcomas.
    Hartmann JT; Oechsle K; Mayer F; Kanz L; Bokemeyer C
    Anticancer Res; 2003; 23(2C):1899-901. PubMed ID: 12820475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of marimastat in advanced pancreatic cancer.
    Evans JD; Stark A; Johnson CD; Daniel F; Carmichael J; Buckels J; Imrie CW; Brown P; Neoptolemos JP
    Br J Cancer; 2001 Dec; 85(12):1865-70. PubMed ID: 11747327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma.
    Reichle A; Bross K; Vogt T; Bataille F; Wild P; Berand A; Krause SW; Andreesen R
    Cancer; 2004 Nov; 101(10):2247-56. PubMed ID: 15470711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palliative chemotherapy with trofosfamide in advanced prostate cancer.
    Salminen EK; Sundström J; Nikkanen V
    Anticancer Res; 2006; 26(1B):539-42. PubMed ID: 16739316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma.
    Milella M; Gelibter A; Di Cosimo S; Bria E; Ruggeri EM; Carlini P; Malaguti P; Pellicciotta M; Terzoli E; Cognetti F
    Cancer; 2004 Jul; 101(1):133-8. PubMed ID: 15221998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II trial of hyperfractionated accelerated chemoradiotherapy for unresectable advanced pancreatic cancer.
    Tsujie M; Nakamori S; Tanaka E; Nagano H; Umeshita K; Dono K; Sakon M; Inoue T; Inoue T; Monden M
    Jpn J Clin Oncol; 2006 Aug; 36(8):504-10. PubMed ID: 16855011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC).
    Nicolini A; Mancini P; Ferrari P; Anselmi L; Tartarelli G; Bonazzi V; Carpi A; Giardino R
    Biomed Pharmacother; 2004 Oct; 58(8):447-50. PubMed ID: 15464874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High response rates in patients with pancreatic cancer using the novel oral fluoropyrimidine S-1.
    Hayashi K; Imaizumi T; Uchida K; Kuramochi H; Takasaki K
    Oncol Rep; 2002; 9(6):1355-61. PubMed ID: 12375048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of oral rubitecan in previously treated pancreatic cancer patients.
    Burris HA; Rivkin S; Reynolds R; Harris J; Wax A; Gerstein H; Mettinger KL; Staddon A
    Oncologist; 2005 Mar; 10(3):183-90. PubMed ID: 15793221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of cyclophosphamide, leucovorin, 5-fluorouracil 24-hour infusion and tamoxifen in pancreatic cancer.
    Eckel F; Lersch C; Lippl F; Assmann G; Schulte-Frohlinde E
    J Exp Clin Cancer Res; 2000 Sep; 19(3):295-300. PubMed ID: 11144522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ifosfamide chemotherapy ineffective for advanced pancreatic carcinoma].
    Fujiki T; Futatsuki K; Akazawa S; Yamamoto K; Kanda Y; Yamato A; Terashi K; Suda Y
    Gan To Kagaku Ryoho; 1997 Mar; 24(5):569-72. PubMed ID: 9087289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
    Bracarda S; Tonato M; Rosi P; De Angelis V; Mearini E; Cesaroni S; Fornetti P; Porena M
    Cancer; 2000 Mar; 88(6):1438-44. PubMed ID: 10717628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
    Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
    J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of weekly 24-h infusion of high-dose 5-fluorouracil in advanced pancreatic cancer.
    Lutz MP; Königer M; Muche R; Ellenrieder V; Steinkamp M; Adler G; Gress TM
    Z Gastroenterol; 1999 Oct; 37(10):993-7. PubMed ID: 10549093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of imatinib mesylate in patients with metastatic pancreatic cancer.
    Gharibo M; Patrick-Miller L; Zheng L; Guensch L; Juvidian P; Poplin E
    Pancreas; 2008 May; 36(4):341-5. PubMed ID: 18437079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of trofosfamide and its dechloroethylated metabolites.
    Hempel G; Krümpelmann S; May-Manke A; Hohenlöchter B; Blaschke G; Jürgens H; Boos J
    Cancer Chemother Pharmacol; 1997; 40(1):45-50. PubMed ID: 9137528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Further evidence for prolongation of survival of pancreatic cancer patients by efficacy orientated sequential polychemotherapy (EOSPC) based on serial tumor marker determinations (CA 19-9/CEA).
    Klapdor R; Bahlo M; Babinsky A
    Anticancer Res; 2005; 25(3A):1687-91. PubMed ID: 16033083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma.
    Marsh Rde W; Rocha Lima CM; Levy DE; Mitchell EP; Rowland KM; Benson AB
    Am J Clin Oncol; 2007 Feb; 30(1):26-31. PubMed ID: 17278891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.